TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00509015

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg)
Description: 500mg S\&25mg P/20 kg, 1 day, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate (day 1,2,3: 4 mg/kg)
Description: 4 mg/kg, daily single dose over three days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine-base (day 3: 0.75 mg/kg)
Description: single dose at 0.75 mg/kg on day 3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo tablets
Description: 3 days of lactose tablets (160mg) albochin
Study: NCT03954145

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Enamel pumicing before bonding the lingual retainer.
Description: Lingual surfaces of the lower incisors and canines are pumiced before bonding the lingual retainer.~Teeth are being cleaned using a brush loaded with pumice and mounted on a low speed contra-angle. Teeth are then etched and the multi-braided retainer wire is being bonded with composite onto the lingual surfaces of the lower canines and incisors.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enamel sandblasting before bonding the lingual retainer.
Description: Enamel is being initially prepared through sandblasting the lingual surfaces of the mandibular canines and incisors.~Sandblasting is performed with the help of a MicroEtcher IIATM (Danville) which is projecting 50 μm Al2O3 particles onto the enamel surfaces. Teeth are subsequently etched and the retainer is then being bonded with composite onto the lingual surfaces of the mandibular incisors and canines.
Study: NCT01595932

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: α-galactosidase
Description: Treatment was administered at the beginning of each meal (3 times a day) for 2 weeks:~children \< 20kg: 4 drops;~children \> 20kg and \< 40kg: 8 drops;~children \> 40kg: 1 tablet.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment was administered at the beginning of each meal (3 times a day) for 2 weeks:~children \< 20kg: 4 drops;~children \> 20kg and \< 40kg: 8 drops;~children \> 40kg: 1 tablet.
Study: NCT04370938

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping strategies video
Description: No additional description
Study: NCT01812174

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 17mm aortic valve (On-X )
Description: Heart aortic valve replacement surgery: 17mm Aortic

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 23mm mitral valve (On-X)
Description: Heart mitral valve replacement surgery: 23mm Mitral
Study: NCT01437072

Intervention type: OTHER
Intervention: No treatment given
Description: The screening test includes a combination of a risk assessment questionnaire and biochemical tests.
Study: NCT02490332

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventilation tube treatment
Description: Tympanostomy
Study: NCT01783301

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FSH

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FSH
Study: NCT01829373

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vaccine 1650-G
Study: NCT05009615

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green coffee extract
Description: 150 mg polyphenols from green coffee, twice daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta glucan
Description: 2.5 g BG twice daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green coffee + beta-glucan
Description: 150 mg polyphenols from green coffee + 2.5 g BG, twice daily
Study: NCT02073552

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol 4000
Description: - Polyethylene glycol 4000: 16 envelopes (70 g of powder each). It includes electrolytes and sodium sulfate. These substances make PEG metabolically inert, achieving a suitable osmotic balance, despite having a high molecular weight. The preparation passes along the gastrointestinal tract without causing net absorption of fluid or electrolytes. It is routinely used in clinical practice for bowel cleansing, before abdominal surgery, barium enema and other colorectal and genitourinary tract tests. Participants will divide the whole doses in 4 liters of water taking half the day before the examination starting at 20.00 h and the other half at 6.00 pm on the day of the examination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macrogol 3350 plus ascorbic acid
Description: - Macrogol 3350 plus ascorbic acid: 4 envelopes, 2 containing 112 g polyethylene glycol and electrolytes and 2 with 2 g of ascorbic acid. The properties of the polyethylene glycol are the same as those mentioned previously, while ascorbic acid generates an osmotic gradient potentiating the effect of polyethylene glycol. It is used routinely as a bowel prep. Participants will divide the doses in 2 liters of water taking half the day before (112 g of PEG and an 11 g of ascorbic acid) the examination at 20.00 h and the other half at 6.00 pm on the day of the examination
Study: NCT01250275

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional canola oil
Description: Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from traditional canola oil.
Study: NCT00747708

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous intracoronary injection
Description: Bone marrow derived stem/progenitor cells or placebo infusion is delivered through an over-the-wire balloon catheter into the target coronary vessels using a stop-flow technique.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous intramyocardial injection
Description: Direct intramyocardial injections of bone marrow derived stem/progenitor cells or placebo will be delivered using the electromechanical NOGA mapping and injection system
Study: NCT03426761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalbavancin
Description: Dalbavancin 1,500mg intravenously every fourteen days for two to four infusions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Examples of standard of care arm; infusions one to three times per day depending on the antibiotic for a total of three to eight weeks
Study: NCT01756833

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: 100 mg po bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule identical to the doxycycline capsule
Study: NCT01250275

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high oleic canola oil
Description: Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from high oleic canola oil.
Study: NCT01961999

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early RRT
Description: In the early arm renal replacement therapy was started on the basis of refractory oliguria: urine output \<0,5ml/Kg/h for \> 6 hours

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Late RRT
Description: In the late arm at least one the following criteria must be fulfilled prior to initiation of renal replacement therapy:~persistent and refractory oliguria (\<0,5ml/Kg/h \>12h), despite therapy refractory extravascular fluid overload azotemia \>40mmol/L or 240mg/dL metabolic acidosis (pH\<7,2) hyperkaliemia (k+\>6mmol/L)
Study: NCT01086397

Intervention type: PROCEDURE
Intervention: Urine sample collection
Description: All subjects have non-invasive urine sample collection performed
Study: NCT04003415

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Device: Contactless heart rate and respiratory rate monitor
Description: Participant will be seated next to the investigational device. The device is contactless, and will measure the patient's heart rate and respiratory rate through use of radio-waves.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Heart Rate (EKG) Monitor
Description: Participant will undergo 3-lead EKG testing to measure heart rate during testing.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Respiratory rate Monitor
Description: Participant will have an elastic band around their chest for monitoring respiratory rate during testing.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pulse Oximetry
Description: Participants will wear a finger pulse oximeter during the testing for monitoring of heart rate, respiratory rate, and pulse oximetry.
Study: NCT01250275

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: soybean oil
Description: Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from soybean oil.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high linoleic safflower oil
Description: Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from high linoleic safflower oil.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: coconut oil
Description: Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from coconut oil.
Study: NCT00065715

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Echinacea
Description: Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. B) Echinacea angustifolia - 600 mg root yields 150 mg dried extract, standardized to contain 2.0 mg alkamides. Each batch of tablets is analyzed by Reversed Phase - High Peformance Liquid Chromatography to determine the levels of alkamides and caffeic derivatives present. Caffeic acid derivative levels are typically as follows: caftaric acid = 0.5 to 2.0 mg/tablet; cichoric acid = 3.4 to 8.5 mg/tablet; chlorogenic acid = \< 0.5 mg/tablet; dicaffeoyl quinic acids (including cynarin) = 0.7 to 2.0 mg/tablet; echinacoside = 1.0 to 1.7 mg/tablet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Echinacea
Description: Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. B) Echinacea angustifolia - 600 mg root yields 150 mg dried extract, standardized to contain 2.0 mg alkamides. Each batch of tablets is analyzed by Reversed Phase - High Peformance Liquid Chromatography to determine the levels of alkamides and caffeic derivatives present. Caffeic acid derivative levels are typically as follows: caftaric acid = 0.5 to 2.0 mg/tablet; cichoric acid = 3.4 to 8.5 mg/tablet; chlorogenic acid = \< 0.5 mg/tablet; dicaffeoyl quinic acids (including cynarin) = 0.7 to 2.0 mg/tablet; echinacoside = 1.0 to 1.7 mg/tablet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Blinded placebo
Description: Blinded placebo - Coated tablet
Study: NCT03931889

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Cap. Cholecalciferol 40,000 IU
Study: NCT03706014

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SIBS Program
Description: Universal prevention program promoting positive sibling and family relationships conducted in an afterschool setting

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Contact-equivalent attention control program in which students play educational games
Study: NCT03375203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered once daily based upon dosing group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered once daily based upon dosing group.
Study: NCT03931889

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: Cap. Cholecalciferol 40,000 IU
Study: NCT01250275

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional canola oil
Description: Participants with peripheral arterial disease (n=25) will be randomized to daily consumption of food items prepared with traditional canola oil for eight weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: safflower oil
Description: Participants with peripheral arterial disease (n=25) will be randomized to daily consumption of foods prepared with an oil mixture representing the typical western diet
Study: NCT01984177

Intervention type: DRUG
Intervention: Corticotropin-Releasing Hormone
Description: Each subject will receive a single dose of Corticotropin-Releasing Hormone corticorelin on a single occasion, and a volume-matched saline injection on a second occasion. Corticorelin will be administered as an intravenous infusion over a 30- to 60-second interval at a dose of 1 ug/kg body weight. \~15 minutes after Corticorelin/saline injection, \[11C\]-(+)-PHNO will be administered followed by 90 minutes of PET scanning. Primary outcome measure (\[11C\]-(+)-PHNO) as well as Secondary outcome measures (self reported feeling, hormones and physiological measures) will be obtained before saline or Corticorelin/saline injection and for 90-120 minutes following injection.

Intervention type: DRUG
Intervention: Corticotropin-Releasing Hormone
Description: Each subject will receive a single dose of Corticotropin-Releasing Hormone corticorelin on a single occasion, and a volume-matched saline injection on a second occasion. Corticorelin will be administered as an intravenous infusion over a 30- to 60-second interval at a dose of 1 ug/kg body weight. \~15 minutes after Corticorelin/saline injection, \[11C\]-(+)-PHNO will be administered followed by 90 minutes of PET scanning. Primary outcome measure (\[11C\]-(+)-PHNO) as well as Secondary outcome measures (self reported feeling, hormones and physiological measures) will be obtained before saline or Corticorelin/saline injection and for 90-120 minutes following injection.
Study: NCT03346915

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WoW and BNI
Description: The Text/web based health information technology system, WoW, will provide educational resources for participants and their families to learn more about HPV vaccination and cervical cancer screening. WoW will be tailored to the participant and will be based on the participant's cancer screening and HPV vaccine health needs; It will then send custom text messages based their concerns and will remind them to schedule and attend their doctor's appointment. The brief negotiated interview will encourage and empower participants to have positive behavioral changes in regards to their health.
Study: NCT04254705

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Rectal Biopsy
Description: Suction biopsy or forceps biopsy
Study: NCT03001531

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HydroSun
Description: a skin area of the lower limb will be treated three times with ultraviolet light emitted by a halogen lamp

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hilotherm
Description: a skin area of the lower limb will be treated three times with heat applied by a sleeve
Study: NCT02396485

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular diet within 6hrs postoperative
Description: Patients will be randomized to regular diet within 6 hrs postoperative (Early group) versus remaining nothing per os (NPO, i.e nothing per mouth) for 12hrs, and the diet then advanced as tolerated after 12hrs (Routine Group) as standard postoperative protocol in the investigators' institution.
Study: NCT01538043

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: local mud-pack therapy and balneotherapy
Description: local mud-pack therapy and thermal-mineral bath at Chianciano Terme Spa Center (Siena, Italy) for a total of 12 applications carried out over a period of two weeks
Study: NCT03431428

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transanal surgery
Description: Transanal surgery could Preserve anus to reduce trauma and improve the quality of life

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Miles surgery
Description: Miles surgery cut off the anus, enlarge the trauma and reduce the quality of life.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Preoperative chemoradiotherapy
Description: After preoperative radiochemotherapy, two cycles of XELOX were given at the interval of waiting operation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy
Description: After preoperative radiochemotherapy, two cycles of XELOX were given at the interval of waiting operation.
Study: NCT00309114

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: bacterial interference

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bacterial interference
Study: NCT01941212

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music therapy
Description: Music therapy will be given to patients 24 hours prior and for the first 48 hours after surgery
Study: NCT00982878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: 150mg twice daily
Study: NCT04692571

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PSICON Measurement Apparatus
Description: Test apparatus acquires 16 sEMG channels, measure four DoFs of force/moment at the hand-wrist \[hand open-close (Opn-Cls); wrist extension-flexion (Ext-Flx), radial-ulnar deviation (Rad-Uln) and pronation-supination (Pro-Sup)\]. sEMG system used 16 custom encased bipolar electrodes. A commercial LTI EMG amplifier (BE328) conditioned each EMG signal before A/D conversion on a PC. A thermoplastic hand cuff secured the wrist to a six-axis load cell (AMTI, model MC3A-100) for force/moment measurement. A separate hand-grasp one-axis load cell (Omega Engineering Inc., model LCR-150) was Velcro-secured between the fingers and the thumb, to measure power grip forces. The PC acquired and stored the sEMG and load cell data, and commanded a triangular screen target. The subject controlled a second triangular cursor. Left-right movement of the cursor was controlled by wrist Ext-Flx, up-down movement by Rad-Uln deviation, cursor rotation by Pro-Sup and cursor size by hand Opn-Cls forces.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PSICON Measurement Apparatus
Description: Test apparatus acquires 16 sEMG channels, measure four DoFs of force/moment at the hand-wrist \[hand open-close (Opn-Cls); wrist extension-flexion (Ext-Flx), radial-ulnar deviation (Rad-Uln) and pronation-supination (Pro-Sup)\]. sEMG system used 16 custom encased bipolar electrodes. A commercial LTI EMG amplifier (BE328) conditioned each EMG signal before A/D conversion on a PC. A thermoplastic hand cuff secured the wrist to a six-axis load cell (AMTI, model MC3A-100) for force/moment measurement. A separate hand-grasp one-axis load cell (Omega Engineering Inc., model LCR-150) was Velcro-secured between the fingers and the thumb, to measure power grip forces. The PC acquired and stored the sEMG and load cell data, and commanded a triangular screen target. The subject controlled a second triangular cursor. Left-right movement of the cursor was controlled by wrist Ext-Flx, up-down movement by Rad-Uln deviation, cursor rotation by Pro-Sup and cursor size by hand Opn-Cls forces.
Study: NCT03132220

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy
Description: Mindfulness-Based Cognitive therapy is a 16 in-person hours intervention. The intervention in this population is designed to reduce symptoms of PTSD and BOS and increase resiliency scores.
Study: NCT01087073

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Activation
Description: Culturally tailored patient activation training classes providing education and communication strategies to empower patients to be proactive in their diabetes self-management behavior. Participants attend a 10 week interactive class. Diabetes support groups after the completion of these classes help patient maintain self-management and adherence to healthy behaviors.
Study: NCT03132220

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Book Club Active Control Intervention
Description: Participants randomized to the book club active control intervention will meet for 16 in-person hours that are broken into sessions. Books will be assigned to read during homework time and discussions regarding the books will occur during the sessions. The time involved will be similar to the MBCT intervention.
Study: NCT00198939

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Family and Cognitive-Behavioral Drug Prevention Intervention
Description: The family therapy component of IFCBT includes engagement, active treatment, and maintenance phases. The cognitive program focuses on harmful effects of drugs and strategies to better manage drug abuse risks. The cognitive-behavioral program introduces youths to problem-solving behavior change principles and study skills to promote school achievement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Family and Cognitive-Behavioral Drug Prevention Intervention
Description: The family therapy component of IFCBT includes engagement, active treatment, and maintenance phases. The cognitive program focuses on harmful effects of drugs and strategies to better manage drug abuse risks. The cognitive-behavioral program introduces youths to problem-solving behavior change principles and study skills to promote school achievement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Family and Cognitive-Behavioral Drug Prevention Intervention
Description: The family therapy component of IFCBT includes engagement, active treatment, and maintenance phases. The cognitive program focuses on harmful effects of drugs and strategies to better manage drug abuse risks. The cognitive-behavioral program introduces youths to problem-solving behavior change principles and study skills to promote school achievement.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Drug education curriculum was delivered to participants assigned to this condition.